This event is drawing attendance from active medtech investors, strategic buyers and the innovators building the future of healthcare.
LAGUNA NIGUEL, Calif.–(BUSINESS WIRE)–#innovation–Christopher J. Velis, Chairman of Miraki Innovation and Co-Founder of Auris Health (acquired by J&J for $5.7B) will deliver the keynote address at the Life Science Intelligence (LSI) Emerging Medtech Summit February 18-20th, 2020 at The Ritz-Carlton in Laguna Niguel, CA.
In his keynote, “The Next Quantum Leaps in Medtech,” Velis will share his insights on a repeatable process for quantum leaps of innovation. He’ll discuss his experiences building companies such as Auris Health and he’ll provide both an investor’s and innovator’s perspective on the future of medtech.
The event is drawing attendance from major medtech investors and strategics looking to partner with new medical device, diagnostic, digital health and other healthtech innovators.
In addition to Velis’ keynote, the event will include over 100 startup CEO presentations, and lively panel discussions with venture capitalists, large corporates, and industry thought leaders.
A full agenda and list of attendees is here.
Investors attending include: JJDC, Sante Ventures, Connecticut Innovations, US Venture Partners, NEA, Pangaea Ventures, SV Health Investors, Miraki Innovation Fund, MVM Partners, Evonik VC, Sands Capital, Mayo Clinic Ventures, HealthTech Capital, Grey Sky Venture Partners, and more.
Strategics attending include: J&J, Medtronic, Boston Scientific, Abbott, Stryker, Edwards Lifesciences, Terumo, Fresenius, Intuitive Surgical, BD, W.L. Gore, and more.
About Life Science Intelligence (LSI)
LSI is a medical technology focused market intelligence & consulting company. We help medtech executives make informed strategic decisions by better understanding market dynamics, trends, opportunities and the competitive landscape.
Contacts
Maricela Almonte
Life Science Intelligence
714 847 3540 Tel
maricela@LS-intel.com
The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…
Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…
- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92%…
Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab…
― Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at…
